Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
Abraxis BioScience, Inc. (NASDAQ: ABBI) announced the tentative approval from FDA to market Irinotecan Hydrochloride Injection, 20 mg/mL, 2 mL, and 5 mL, the generic equivalent of Camptosar Injection manufactured by Pfizer Inc.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
